Skip To Main Content
Amy Brown on Muck Rack

Amy Brown

London
As seen in: BiotechTV, BMJ Open, Citeline, In Vivo, Evaluate, Yachts and Yachting, The Gryphon, ApexOnco
UK-based contributor for @BiotechTVHQ, and freelance writer on the business of drug development.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Amy

Contact Amy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Identifying lifelong factors that impact brain health and functional outcomes in adults with childhood-onset type 1 diabetes: the cognition and longitudinal assessments of risk factors over 30 years (CLARiFY) - diabetes complications study protocol | BMJ

|
By Amy Brown, Stacey A. Sakowski, Chris Moran, Emily J. Koubek
| BMJ Open Verified
Sample size justification Based on consent rates for participants in the original RCH T1D Cohort Study from previous waves of follow-up data collection, we expect to enrol n=100 of the n=134 original T1D participants.
Open in Who Shared Issue with article?

BridgeBio’s oncology spinout must stand out from the crowd

|
By Amy Brown
| ApexOnco
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues. A new kid on the oncology block emerged last week, with the spin out of BridgeBio’s oncology unit. Formerly known as TheRas, and now named BridgeBio Oncology, the private group has $200m of new money in the bank and a pipeline of three early-stage projects.
Open in Who Shared Issue with article?

A Calquence win seven years in the making

|
By Amy Brown
| ApexOnco
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene. AstraZeneca’s Calquence looks to have succeeded where Pfizer’s Ibrance failed, by helping patients with untreated mantle cell lymphoma live longer. The Echo trial hit its progression free survival endpoint and a trend to a benefit on overall survival was seen, the company said.
Open in Who Shared Issue with article?
See all 708 articles